Skip to main content
. 2016 Feb 3;7(9):10228–10242. doi: 10.18632/oncotarget.7169

Figure 8. NMU signaling positively regulates growth factor-driven mesenchymal marker expressions in the grade II endometrial cancer cell lines.

Figure 8

The transcript levels of (A) CDH2 (N-cadherin) and (B) VIM (vimentin), and (C) the protein levels of CDH2 and VIM were compared between control and NMU-knockdown RL95-2 cells in the absence or presence of EGF (10 ng/ml) or TGFβ1 (3 ng/ml) treatment. In addition, the transcript levels of (D) CDH2 and (E) VIM, and (F) the protein levels of CDH2 and VIM were compared between eGFP-overexpressing and NMUR2-overexpressing HEC1A cells treated with 100 nM NMU in the absence or presence of EGF or TGFβ1. The transcript levels from real-time PCR were normalized against ACTB and are shown as the mean ± SD. *p < 0.05. The corresponding proteins were detected by Western blotting using ACTB as the internal control.